LETROZOL AMAROX 2.5MG FTA Amarox

Description

Indications for LETROZOL AMAROX 2.5MG FTA Amarox

Adjuvant therapy of hormone-positive invasive early breast cancer in postmenopausal women.
Extended adjuvant therapy of early-stage breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.
First-line therapy in women with hormone-dependent advanced breast cancer in postmenopausal women.
Treatment of advanced breast cancer in postmenopausal women (natural or artificially induced) after recurrence or progression of disease who have received prior anti-estrogen therapy.
Neoadjuvant therapy in postmenopausal women with hormone-positive, HER-2-negative breast cancer who are not suitable for chemotherapy and are not indicated for urgent surgical intervention.
The efficacy of the drug for patients with hormone-negative breast cancer has not been proven.

Contraindications

• Hypersensitivity to the active substance or to any other component of the drug.
• Endocrine status characteristic of premenopausal period.
• Pregnancy, lactation period.
• Women of reproductive age.